Pharma & Bio
Technology
Onconic Surges on Jaqbo’s Approval in India [K-Bio Pulse]
South Korea’s pharmaceutical and life sciences sectors rose in tandem on Aug. 6, led by Onconic Therapeutics, Qurient, and Voronoi.The pharmaceutical index gained 2.24%, with 97 of 161 stocks closing …
Lifestyle
Onconic Soars on Jakuvo Approval in India… Qurient Co., Ltd. and Voronoi, Inc. Also Gain Ground [Bio Spotlight]
On the 6th, the pharmaceutical and life sciences sectors rose in tandem on the domestic stock market. The pharmaceutical sector rose 2.24% from the previous trading day. Of the 161 stocks in the secto…
Lifestyle
[Expert Insight] Min Kyung-jun, Director of Newmin Hospital: “The Paradigm in Joint Treatment Is Shifting Toward ‘Conservation’… Keep an Eye on CartiLife”
“Knee cartilage lacks blood vessels, so once damaged, it is difficult to recover naturally. Rather than enduring the pain, it is important to accurately diagnose the extent of the damage and choose a …
Lifestyle
“Human Hair Follicles Regrew”… Orient Bio’s OND-1 Is 10 Times More Effective Than Minoxidil in Treating Hair Loss
“We shouldn’t make claims about a new hair-growth drug based solely on a photo showing hair growing on a mouse’s back. The key is how much lower the concentration is compared to existing treatments, a…
Lifestyle
D&D Pharmatech Plummets 18% After Pfizer Halts ORALINK Candidate [K-bio pulse]
D&D Pharmatech shares fell sharply after it was confirmed that development had been halted on an obesity drug candidate built using the company’s technology. Coming on the heels of questions about Pep…
Lifestyle
D&D Pharmatech Inc. Falls 18% Despite Clarification… ‘Expectations for K’s Obesity Treatment’ Shaken [Bio Spotlight]
D&D Pharmatech Inc.’s stock price fell sharply after it was confirmed that research and development on an obesity treatment candidate incorporating D&D Pharmatech Inc.(347850)’s technology had been su…
Technology
South Korea’s Regulatory Overhaul and U.S. Tariff Exemptions… SAMSUNG BIOLOGICS Among Direct Beneficiaries in the Spotlight
Regulatory changes in both South Korea and the United States are simultaneously shaking up the business environment for domestic Contract Development and Manufacturing Organizations (CDMOs). In South …
Lifestyle
Gil Young-jun, CEO of Huino: “Memocue Is Gaining Momentum Rapidly... Expecting to Turn a Profit Next Year”
Huino, which began as South Korea’s first information and communications technology (ICT) regulatory sandbox biotech venture, has overcome the high regulatory barriers in the remote monitoring market …
Technology
Inbosa in 2020: October Is the Final Showdown… Will Kolon TissueGene, Inc. Keep Pushing Forward Even If It Fails Again?
Kolon TissueGene, Inc.(950160) TG-C (formerly Invossa), a cell- and gene-based therapy for osteoarthritis, has once again reached a crossroads. After failing to meet the co-primary endpoints in its fi…
Technology
[Exclusive] Competition Heats Up to Win Over Hospitals… Concerns Over a ‘Chicken Game’ in the AI Patient Monitoring Market
“A competitor has offered a product we were supplying for 3.5 million won at around 1 million won. At that price, there’s virtually no way for us to compete.”Price competition to secure a foothold in …